Solid Tumor Oncology Education Foundation Sponsors Free Local Seminars

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 9
Volume 5
Issue 9

SECAUCUS, NJ--To accommodate community-based physicians who may not be able to attend national professional meetings, the newly formed not-for-profit Solid Tumor Oncology Education Foundation, Inc. will sponsor a series of free local seminars and audioconferences, led by a faculty of expert physicians.

SECAUCUS, NJ--To accommodate community-based physicians who maynot be able to attend national professional meetings, the newlyformed not-for-profit Solid Tumor Oncology Education Foundation,Inc. will sponsor a series of free local seminars and audioconferences,led by a faculty of expert physicians.

The programs will focus on breast, colorectal, gastrointestinal,genitourinary, gynecologic, pancreatic, and lung cancers, andinclude such subjects as adjuvant and palliative therapy, currentand new protocol regimens, screening and diagnosis, and quality-of-lifeissues.

Beginning this month, the Foundation will offer a series of presentationsconducted at local, state, and regional oncology meetings by leadingoncolo-gists, as well as telephone audioconfer-ences, allowinghealth-care professionals to participate from their home or office.

The chairman of the Foundation is Paul A. Bunn, Jr., MD, Universityof Colorado Cancer Center. Board members are Laurence H. Baker,DO, University of Michigan Comprehensive Cancer Center; GabrielN. Hortobágyi, MD, University of Texas M.D. Anderson CancerCenter; John S. Macdonald, MD, Temple University Cancer Center;Robert F. Ozols, MD, PhD, Fox Chase Cancer Center, and ElizabethJ. Shpall, MD, University of Colorado Health Sciences Center.

The formation of the Foundation was made possible by an unrestrictededucational grant from Lilly Oncology. Oncolo-gists can get moreinformation by calling 1-800-223-8978.

Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content